文献速递耳科与耳神经头颈外科

接受顺铂和放疗的头颈癌患者的听力学随访

Audiologic Follow-up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation.
PubMed 文献 · Laryngoscope · 2023-03-30

单机构回顾性队列研究分析294例接受顺铂和放疗的头颈癌患者,220例(74.8%)有至少一次治疗后听力图,3个月随访率最高(170例,57.8%),6个月后随访率急剧下降;无保险和IV期癌症与完全失访相关(aOR分别为7.18和1.96);156例被推荐助听器的患者中仅39例(24.8%)获得助听器。

要点

  • 74.8%患者有至少一次治疗后听力图,但仅20.0%有超过一次。
  • 3个月随访率最高(57.8%),其余时间点随访率7.1%至14.3%。
  • 无保险和IV期癌症与完全失访相关(aOR分别为7.18和1.96)。

核心结论

  • 参加耳毒性监测项目的头颈癌患者至少一次治疗后听力图的随访率中等偏高,但6个月后随访率急剧下降,助听器使用率低;需要进一步研究了解长期听力学随访和助听器使用的障碍,以减少癌症生存者中未治疗的听力损失。

研究设计与样本

  • 单机构回顾性队列研究,纳入294例接受顺铂和放疗并参加耳毒性监测项目的头颈癌成人患者。

主要发现

  • 294例患者中,220例(74.8%)有至少一次治疗后听力图,58例(20.0%)有超过一次听力图。
  • 随访率最高的时间点为3个月(n=170,57.8%),其余时间点随访率范围为7.1%至14.3%。
  • 控制协变量后,无保险患者与完全失访听力学随访相关(aOR=7.18,95%CI=2.75-19.90),IV期癌症患者与完全失访听力学随访相关(aOR=1.96,95%CI=1.02-3.77)。
  • 156例被推荐助听器的患者中,仅39例(24.8%)获得助听器。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Evaluate factors associated with adherence to ototoxicity monitoring among patients with head and neck cancer treated with cisplatin and radiation therapy at a tertiary care center. METHODS: We performed a single-institution retrospective cohort study on adults with head and neck cancer treated with cisplatin and radiation therapy who participated in an ototoxicity monitoring program. The primary outcomes were rates of post-treatment audiograms at the following time points: one, three, six, 12, and greater than 12 months. Multivariable logistic regression was performed to identify risk factors associated with complete loss of follow-up after pre-treatment evaluation. RESULTS: Two hundred ninety-four head and neck cancer patients were analyzed. Overall, 220 (74.8%) patients had at least one post-treatment audiogram; 58 (20.0%) patients had more than one audiogram. The time point with the highest follow-up rate was at 3 months (n = 170, 57.8%); rates at the remaining times ranged from 7.1% to 14.3%. When controlling for covariates, patients without insurance and those with stage IV cancers were associated with complete loss of audiologic follow-up (aOR = 7.18, 95% CI = 2.75-19.90; aOR = 1.96, 95% CI = 1.02-3.77, respectively). Among 156 patients recommended for a hearing aid, only 39 (24.8%) patients received one. CONCLUSIONS: Head and neck cancer patients enrolled in an ototoxicity monitoring program demonstrate moderately high follow-up rates for at least one post-treatment audiogram. However, follow-up tapers dramatically after 6 months, and overall hearing aid utilization is low. Further research is needed to understand barriers to long-term audiologic follow-up and hearing aid utilization to decrease untreated hearing loss in cancer survivorship. LEVEL OF EVIDENCE: Level 3 Laryngoscope, 133:3161-3168, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Lee DS, Travis EY, Wong SK, et al. Audiologic Follow-up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation. Laryngoscope. 2023. PMID: 36995150. doi:10.1002/lary.30682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。